Global Sickle Cell Anemia Testing & Screening Market Analysis and Forecast 2024-2030 - Rising Focus on Development of Non-Invasive, Hand-Held, and Digital Technologies
14 juin 2024 05h23 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Global Sickle Cell Anemia Testing & Screening Market by Technology (Hemoglobin Electrophoresis, High-performance Liquid Chromatography (HPLC),...
Comprehensive Analysis of Hematology Collaboration and Licensing Deals (2016-2024) Unveiled
02 mai 2024 05h25 HE
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Hematology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.A thorough report on hematology...
Global Iron Deficiency Anemia Therapy Market Poised for Growth, Forecasted to Reach $4.6 Billion by 2030
01 févr. 2024 10h05 HE
|
Research and Markets
Dublin, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The "Iron Deficiency Anemia Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
Global Iron Deficiency Anemia Therapy Market Analysis 2024-2034 Featuring Profiles of Leading Players Including AbbVie, Bayer, CSL Vifor, Sanofi, and Teoxane
24 janv. 2024 14h20 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Iron Deficiency Anemia Therapy Market Analysis & Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
09 déc. 2023 17h02 HE
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
08 déc. 2023 09h10 HE
|
Spherix Global Insights
Exton, Pennsylvania, Dec. 08, 2023 (GLOBE NEWSWIRE) -- EVRENZO made history as the initial hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to receive EU approval in August 2021,...
Global Hematology Collaboration and Licensing Agreements Analysis Report 2023: In-depth Understanding of Hematology Trends and Structure of Deals by Leading Biopharma Companies
16 nov. 2023 07h18 HE
|
Research and Markets
Dublin, Nov. 16, 2023 (GLOBE NEWSWIRE) -- The "Hematology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Hematology Collaboration and...
Global Chemotherapy-Induced Anemia Market Forecast to 2027: Projections for RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), and Iron Supplementation Treatments
01 nov. 2023 08h33 HE
|
Research and Markets
Dublin, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The "Global Chemotherapy-Induced Anemia Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global chemotherapy-induced...
FibroGen to Report Third Quarter 2023 Financial Results
23 oct. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
Sickle Cell Disease Treatment Market to hit USD 7.79 billion by 2032, says Global Market Insights Inc.
10 sept. 2023 18h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Sept. 10, 2023 (GLOBE NEWSWIRE) -- Sickle Cell Disease Treatment Market size is expected to be worth USD 7.79 billion by 2032. SCD is a genetic disorder that affects millions...